Literature DB >> 20477096

Respiratory syncytial virus: immunopathology and control.

Weidong Zhang1, Richard F Lockey, Shyam S Mohapatra.   

Abstract

Respiratory syncytial virus (RSV) is the primary cause of serious upper and lower respiratory tract infections in infants and children worldwide. RSV infection in infancy may lead to the onset of asthma or other health problems later in life. An effective vaccine is not yet available against RSV infection. Humans respond to RSV infection by mounting an immune response, but the antiviral immunity is incomplete, thus repeat RSV infections continue throughout life. The precise mechanism of RSV-induced infection and immunopathology remains unclear. The limited knowledge of RSV immunity is a major problem in designing a protective vaccine. In this review, the biology of RSV infection, its immunopathology, the role of innate and adaptive immunity, as well as the understanding of how to control RSV infection based on prophylactic and therapeutic approaches are discussed.

Entities:  

Year:  2006        PMID: 20477096     DOI: 10.1586/1744666X.2.1.169

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  3 in total

Review 1.  Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity.

Authors:  Diego R Hijano; Luan D Vu; Lawrence M Kauvar; Ralph A Tripp; Fernando P Polack; Stephania A Cormier
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

2.  Ultrafast-UV laser integrating cavity device for inactivation of SARS-CoV-2 and other viruses.

Authors:  Sharad Ambardar; Mark C Howell; Karthick Mayilsamy; Andrew McGill; Ryan Green; Subhra Mohapatra; Dmitri V Voronine; Shyam S Mohapatra
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

Review 3.  The infectious march: the complex interaction between microbes and the immune system in asthma.

Authors:  Terianne Wong; Gary Hellermann; Shyam Mohapatra
Journal:  Immunol Allergy Clin North Am       Date:  2010-11       Impact factor: 3.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.